Please note, this OEL/ADE monograph also applies to clarithromycin citrate (CAS RN 848130-51-8) and clarithromycin lactobionate (CAS RN 135326-55-6). Clarithromycin is indicated for the treatment of susceptible bacterial infections including acute infective exacerbation of chronic bronchitis, acute otitis media, community acquired pneumonia, disseminated infection due to Mycobacterium avium-intracellulare group, disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection, duodenal ulcer disease - Helicobacter pylori gastrointestinal tract infection, uncomplicated infection of skin and/or subcutaneous tissue, acute maxillary sinusitis, mycobacterium avium complex infection with lung disease, and streptococcal pharyngitis.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Clarithromycin, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.